Molecular Partners AG MLLCF
Set alert
4.01 USD 0.00 0.00%
At close · Oct 30
2.55 Day range 2.55
2.25 52-week range 4.85
- YTD
- +14.57%
- 1 year
- +11.39%
- Open
- 2.55
- Prev close
- 4.01
- Mkt cap
- 153.73M
- Vol
- 100
- Avg vol
- 79
- EPS
- -1.68
- P/E
- 0.00
More statistics
- Low
- 2.55
- High
- 2.55
1Y chart
Signals (28)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Sep 22, 2026 | 1 month ago |
| RSI: Overbought | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 23, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 17, 2026 | 4 months ago |
| SMA: Bullish | May 28, 2026 | 5 months ago |
| MACD: Buy Signal | May 28, 2026 | 5 months ago |
| RSI: Overbought | May 28, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 15, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Apr 10, 2026 | 6 months ago |
| SMA: Bearish | Apr 10, 2026 | 6 months ago |
| SMA: Bullish | Apr 7, 2026 | 6 months ago |
| SMA: Bullish | Apr 7, 2026 | 6 months ago |
| RSI: Overbought | Apr 7, 2026 | 6 months ago |
| MACD: Buy Signal | Feb 12, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 26, 2026 | 9 months ago |
| RSI: Oversold | Jan 26, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 16, 2026 | 9 months ago |
| SMA: Bearish | Dec 19, 2025 | 10 months ago |
Newest 20 of 28.
News
- Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript
- Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Molecular Partners AG (MOLN) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program Transcript
- Molecular Partners AG (MOLN) Q4 2024 Earnings Call Transcript
- Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript
- Molecular Partners AG (MOLN) Q4 2022 Earnings Call Transcript
- Molecular Partners AG (MOLN) Q2 2022 Earnings Call Transcript
- Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant
- Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States
- Molecular Partners Announces First Patient Dosed in COVID-19 NIH-Sponsored ACTIV-3 Trial Evaluating Antiviral Candidate Ensovibep
Your note
Sign in to keep a note on MLLCF — it syncs with the Stock Master app.